Conventional wisdom frames aging as a linear decline — entropy made biological. But the preclinical literature on bioregulatory signalling molecules suggests something more mechanistically specific: aging proceeds through discrete, addressable molecular failures. Telomere erosion. NAD+ depletion. Dysregulated gene expression. These are not vague correlates of getting old — they are measurable, targetable, and in model organisms, partially reversible.

The Longevity Stack brings together three research compounds — Epithalon, GHK-Cu, and NAD+ — that have each accumulated independent mechanistic evidence across these failure modes. Epithalon acts at the telomere and epigenetic level. GHK-Cu resets broad transcriptional programmes and activates stress-response pathways. NAD+ sustains the metabolic and sirtuin infrastructure that makes those gene expression changes possible.

What makes this stack worth understanding is not that any single compound does everything. It is that the three compounds address distinct but interconnected nodes: telomere biology, extracellular matrix and gene regulation, and mitochondrial energy metabolism. Each pathway has preclinical support. The convergence between them — particularly at the SIRT1 node — is mechanistically coherent, even though the combination itself has not been studied directly in the peer-reviewed literature.

This post reviews the evidence for each compound independently, maps the mechanistic convergence points, and then does something most longevity content skips entirely: states the limitations plainly. What the data supports, what it cannot yet tell us, and where the gaps remain large enough to matter.

Background & Methods

What the Research Examined

The evidence base for this stack draws from three independent research traditions that have rarely been studied in combination.

Epithalon (AEDG tetrapeptide) has been investigated primarily by Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology across several decades. The foundational in vitro work used human fetal fibroblast cultures to demonstrate telomerase activation and telomere elongation (Khavinson VKh et al., 2004, PMID: 15455129). Subsequent molecular modelling and stem cell studies examined the epigenetic mechanism — specifically, Epithalon’s preferential binding to histone H1/3 and H1/6 subunits (Khavinson V et al., 2020, PMID: 32019204). Animal model lifespan data comes from Drosophila melanogaster (Khavinson VK et al., 2000, PMID: 11087911) and rodent bioregulator protocols reported in review literature spanning 6–12 year observation periods (Anisimov VN et al., 2010, PMID: 19830585).

GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper complex) research spans in vivo rat wound chamber models, in silico Connectivity Map gene expression analysis, and in vitro cellular senescence studies. The foundational in vivo work used rat wound chambers with sequential GHK-Cu injections to measure extracellular matrix accumulation directly (Maquart FX et al., 1993, PMID: 8227353). Gene expression modelling using the Broad Institute Connectivity Map identified over 1,000 genes modulated by GHK across inflammation, DNA repair, and neurodegeneration pathways (Pickart L et al., 2017, PMID: 28212278). The most recent mechanistic data, from a 2024 in vitro nanocarrier study, confirmed Nrf2 and SIRT1 pathway activation specifically in the context of oxidative senescence (Wang Y et al., 2024, PMID: 38394858).

NAD+ research now spans a systematic review of 147 studies (Braidy N et al., 2020, PMID: 31917996), molecular pathway studies examining the NAMPT rate-limiting step (Khaidizar FD et al., 2021, PMID: 33918226), and several small human RCTs using NR and NMN formulations. Relevant human trials include a crossover RCT in 22 older adults (Vreones M et al., 2023, PMID: 36515353), a 32-participant dose-escalation trial of oral NMN (Pencina KM et al., 2023, PMID: 35182418), and a 2024 RCT in adults with mild cognitive impairment that measured epigenetic clock outcomes directly (Orr ME et al., 2024, PMID: 37994989).

Dosing ranges studied across these models vary considerably. Epithalon in Drosophila studies was effective at concentrations as low as 0.001×10⁻⁶ wt.% of culture medium. Rodent bioregulator protocols used subcutaneous or intranasal routes. Human NAD+ precursor RCTs used 500 mg–1,000 mg oral doses of NR or NMN. GHK-Cu in vitro concentrations used in gene expression studies are not directly translatable to systemic dosing contexts.

Results & Mechanisms

Epithalon: Telomere Biology and Epigenetic Regulation

The most cited mechanism for Epithalon is telomerase activation. In Khavinson et al. (2004), primary pulmonary fibroblasts derived from a 24-week human fetus were cultured to passage 34, at which point cells lost proliferative potential and showed shortened telomeres. Addition of Epithalon induced telomere elongation to sizes comparable to early-passage cells (passage 10), and treated cells completed approximately 10 additional divisions — passage 44 versus passage 34 in controls — before reaching senescence arrest (PMID: 15455129). This is the clearest published demonstration of Epithalon overcoming the Hayflick limit in a human cell model.

The epigenetic mechanism was clarified in 2020. Molecular modelling showed Epithalon preferentially binds histone H1/3 and H1/6 subunits at sites that interact directly with DNA. In human gingival mesenchymal stem cells, this binding was associated with increased mRNA expression of neurogenic differentiation markers — Nestin, GAP43, β-Tubulin III, and Doublecortin — by 1.6–1.8× over control (Khavinson V et al., 2020, PMID: 32019204). The mechanism proposed is epigenetic: histone H1 modulation changing local chromatin accessibility and downstream transcription.

In aged rat models, Epithalon demonstrated antioxidant properties distinct from and exceeding direct melatonin activity, specifically through upregulation of endogenous superoxide dismutase (SOD) and ceruloplasmin expression (Kozina LS et al., 2007, PMID: 17317455). This matters for longevity biology because SOD is a primary enzymatic defence against mitochondrial superoxide — a key driver of cellular aging.

Lifespan data in model organisms is notable. In Drosophila melanogaster (Canton-S wild strain), Epithalon produced 11–16% mean lifespan increases across a range of concentrations 16,000–80,000,000 times lower than effective melatonin concentrations (Khavinson VK et al., 2000, PMID: 11087911). In longer-term rodent protocols, peptide bioregulator regimens including Epithalon were associated with 20–40% mean lifespan increases and suppression of spontaneous tumorigenesis (Anisimov VN et al., 2010, PMID: 19830585).

Table 1: Epithalon Preclinical Evidence Summary

GHK-Cu: Extracellular Matrix, Gene Reset, and Sirtuin Convergence

GHK-Cu is an endogenous copper-binding tripeptide complex. Plasma concentrations decline from approximately 200 ng/mL in young adults to approximately 80 ng/mL in older adults — a ~60% reduction that provides a physiological rationale for studying exogenous administration in aging contexts (Pickart L et al., 2017, PMID: 28212278).

The foundational in vivo data comes from rat wound chambers. Maquart et al. (1993) demonstrated that sequential GHK-Cu injections produced a concentration-dependent increase in dry weight, DNA, total protein, collagen, and glycosaminoglycan content in wound chambers. Critically, collagen synthesis was stimulated at twice the rate of non-collagen proteins. Type I and Type III collagen mRNAs were both elevated; TGF-β mRNAs were not — suggesting a direct transcriptional mechanism rather than TGF-β-mediated secondary signalling (PMID: 8227353). For longevity biology, the extracellular matrix remodelling capacity of GHK-Cu is relevant to skin, connective tissue, and vascular integrity — structural components that deteriorate meaningfully with age.

The broader gene expression story is more ambitious. Using the Broad Institute Connectivity Map, Pickart and Margolina (2017) identified GHK as a modulator of over 1,000 human genes, with the consistent finding that pathological gene expression patterns — including those associated with inflammation, oxidative damage, DNA repair deficits, and neurodegeneration — were reset toward healthier baseline profiles (PMID: 28212278). This in silico analysis is hypothesis-generating rather than confirmatory, but the breadth of affected pathways is unusually large for a single molecule.

The most mechanistically relevant recent finding for the longevity stack context is the 2024 confirmation that GHK-Cu activates Nrf2 and SIRT1 signalling pathways specifically in the context of oxidative stress-induced cellular senescence. Wang et al. (2024) showed that GHK-Cu encapsulated in nanocarriers regulated Nrf2, SIRT1, and PGC-1α/COX-2-related pathways, counteracting senescence, inflammation, and apoptosis from oxidative damage in cellular models (PMID: 38394858). The SIRT1 activation here is the critical bridge to NAD+ biology within this stack.

NAD+: The Metabolic and Sirtuin Infrastructure

NAD+ (nicotinamide adenine dinucleotide) functions as an obligate cofactor for two sets of enzymes central to aging biology: sirtuins (SIRT1–SIRT7), which require NAD+ as a co-substrate for their deacetylase activity, and PARPs (poly ADP-ribose polymerases), which consume NAD+ to execute DNA strand-break repair.

The problem is that NAD+ levels decline with age. The mechanism involves the rate-limiting enzyme NAMPT (nicotinamide phosphoribosyltransferase), which controls flux through the NAD+ salvage pathway — the dominant biosynthetic route in most mammalian tissues. NAMPT expression falls with aging, creating a self-reinforcing deficit: less NAMPT → less NAD+ → less SIRT1 activity → impaired mitochondrial biogenesis → more oxidative DNA damage → more PARP activation → further NAD+ depletion (Khaidizar FD et al., 2021, PMID: 33918226; Maynard S et al., 2022, PMID: 36099415).

In a D-galactose-induced aging mouse model (2025), NAD+ pretreatment of mesenchymal stromal cells significantly improved grip strength (p=0.0009), running endurance (p=0.0169), and muscle fibre cross-sectional area (p=0.0014), while reducing Atrogin-1 and MuRF1 atrophy markers. The mechanism was traced precisely: NAD+ enhanced NAMPT secretion, which activated the SIRT1/PGC-1α signalling pathway and improved mitochondrial function and fatty acid oxidation in skeletal muscle (Song J et al., 2025, PMID: 41383117).

The human data, while limited in scale, shows target engagement. In a double-blind RCT, oral NMN (MIB-626, 1,000 mg/day) produced blood NMN concentrations 1.7× above baseline with once-daily dosing and 3.7× above baseline with twice-daily dosing in adults aged 55–80 over 14 days (Pencina KM et al., 2023, PMID: 35182418). In a crossover RCT of 22 healthy older adults, oral NR (500 mg twice daily, 6 weeks) increased NAD+ in neuronal-origin extracellular vesicles and reduced Aβ42, pJNK, and pERK1/2 — markers related to neuroinflammation and insulin resistance — compared to placebo (Vreones M et al., 2023, PMID: 36515353).

Most directly relevant to longevity endpoints: in a 2024 RCT in adults with mild cognitive impairment, NR supplementation at 1 g/day produced a 2.6-fold increase in blood NAD+ (p<0.001) and a statistically significant reduction in epigenetic age as measured by both PhenoAge and GrimAge clocks, alongside a modest increase in global DNA methylation (Orr ME et al., 2024, PMID: 37994989). This is, to our knowledge, the clearest published demonstration of NAD+ precursor supplementation producing a measurable epigenetic age reduction in humans.

Table 2: NAD+ and GHK-Cu Evidence Summary

Mechanistic Convergence Within the Stack

Three non-redundant mechanisms operate in parallel across this stack, with one notable node of convergence:

Parallel antioxidant arms: Epithalon upregulates endogenous SOD and ceruloplasmin — enzymatic defences against mitochondrial superoxide. GHK-Cu activates Nrf2, driving downstream phase II antioxidant enzymes including HO-1 and NQO1. NAD+ sustains PARP-mediated DNA repair and provides the co-substrate for SIRT1-mediated redox regulation. These are three mechanistically distinct antioxidant pathways, not redundant ones.

Epigenetic and telomere biology: Epithalon acts at the telomere/histone H1 level, potentially maintaining replicative capacity and transcriptional accessibility. NAD+ supplementation reduces epigenetic age as measured by methylation clocks. GHK-Cu resets broad transcriptional programmes across inflammation and repair pathways. Together these address epigenetic aging at the telomere, chromatin, methylation, and gene expression levels simultaneously.

SIRT1 convergence: This is the most mechanistically specific intersection. GHK-Cu activates SIRT1 directly in cellular models (PMID: 38394858). NAD+ is the obligate co-substrate that SIRT1 requires to function — without adequate NAD+, SIRT1 activity collapses regardless of upstream signals (PMID: 36099415). The combination of a SIRT1 activator (GHK-Cu) with a SIRT1 co-substrate replenisher (NAD+) represents a coherent mechanistic pairing. Whether this produces additive or synergistic effects in vivo has not been tested. The inference is logical; the empirical confirmation does not yet exist.

Researchers interested in the broader context of stack design can explore the Hallmarks Stack (NAD+, MOTS-c, Epithalon, GHK-Cu) and the Khavinson Triple in our Research Stacks catalogue for related combination approaches. Our Research Notes section covers stack sequencing considerations in more detail.

Discussion & Limitations

This is where most longevity content goes quiet. We will not.

Limitation 1: The Epithalon literature comes almost entirely from one research group. The overwhelming majority of Epithalon studies are authored by or directly affiliated with V.Kh. Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. Independent replication by external groups is virtually absent in the indexed literature. The 6–12 year “clinical application” data referenced in Anisimov and Khavinson (2010, PMID: 19830585) lacks RCT methodology, blinding, or placebo controls as evaluated by contemporary standards. This does not invalidate the findings — the mechanistic in vitro data is reproducible in principle — but the absence of independent replication is a significant epistemic limitation. Publication bias from a single institutional source is a real concern.

Limitation 2: NAD+ human trials are small and short. The most rigorous human studies in this review involve n=20 to n=32 participants over 6–14 week durations. These trials are underpowered to detect longevity endpoints in any meaningful sense. The epigenetic clock reductions in Orr et al. (2024, PMID: 37994989) are genuinely interesting — a 2.6-fold NAD+ increase with measurable GrimAge and PhenoAge reduction is not a trivial signal — but these were exploratory secondary outcomes in a study designed primarily around cognitive measures. They would not survive multiple comparisons correction in a confirmatory design. The pharmacokinetic data (Pencina et al., 2023, PMID: 35182418) establishes target engagement clearly. What remains unknown is whether sustained NAD+ elevation over months or years translates to longevity outcomes in humans, rather than in mouse models.

Limitation 3: GHK-Cu has no human longevity trial. The gene expression data from the Connectivity Map analysis (PMID: 28212278) is in silico — it identifies what GHK could do to transcription based on pattern matching, not what it demonstrably does in a living human. The 2024 cellular senescence data (PMID: 38394858) is in vitro. The foundational wound chamber data (PMID: 8227353) is in vivo but in rats, measuring localised tissue response to direct injection. Systemic administration in humans with longevity endpoints has not been studied. The argument for GHK-Cu in a longevity context is mechanistically compelling — the SIRT1/Nrf2 convergence is real, the age-dependent plasma decline is documented — but it rests substantially on inference from isolated biological observations rather than integrated human outcome data.

Limitation 4: The combination has not been studied. This deserves its own entry. Epithalon, GHK-Cu, and NAD+ have been examined individually across multiple model systems. No published peer-reviewed study has examined their co-administration, interaction profile, pharmacokinetics, or combined biological effect. The SIRT1 convergence is a mechanistically coherent inference. It is not an empirical observation. There may be interactions — competitive, additive, or synergistic — that no current data can predict.

Limitation 5: Oral bioavailability of signalling molecule compounds remains incompletely characterised. The 2024 nanocarrier study (PMID: 38394858) was designed specifically because GHK-Cu faces gastrointestinal proteolytic degradation. Epithalon, as a tetrapeptide of approximately 432 Da molecular weight, faces similar gastric degradation challenges. Oral bioavailability data for these specific compounds has not been rigorously established in published human pharmacokinetic studies. Formulation matters significantly, and this remains an active problem rather than a solved one.

Limitation 6: Potential risks of chronic NAD+ elevation are under-studied. The Braidy systematic review (2020, PMID: 31917996) explicitly notes theoretical risks of chronically elevated NAD+, including accumulation of putative toxic metabolites such as methylnicotinamide, and the theoretical possibility of supporting tumorigenesis in cancer-prone cellular contexts. Long-term safety data beyond 12 months in humans does not exist in the published literature. This is not a reason to dismiss NAD+ research — but it is information the informed self-optimiser should have.

For researchers exploring related longevity compound profiles, our Longevity Compounds section and Research Notes provide additional compound-level summaries.

Conclusion

The Longevity Stack — Epithalon, GHK-Cu, and NAD+ — is the most mechanistically layered combination in the biohacker.team catalogue. Each compound addresses a distinct node in aging biology. Epithalon works at the telomere and histone level, with the most compelling evidence for preserving replicative capacity in cell culture and extending mean lifespan in model organisms. GHK-Cu resets transcriptional programmes at scale, activates the Nrf2 antioxidant response, and — critically — activates SIRT1 directly. NAD+ replenishes the co-substrate that SIRT1 requires to function and has produced measurable epigenetic age reductions in the most recent human RCT data.

The mechanistic convergence at SIRT1 is the most intellectually interesting feature of this combination. It is also entirely uninvestigated as a co-administered protocol. The data supports each component individually. The stack framing is an inference, not a finding.

For researchers constructing longevity-focused protocols, the individual compound evidence base here is among the strongest in preclinical aging literature — particularly for NAD+, which now has multiple small human RCTs with target engagement confirmed. Epithalon and GHK-Cu rely more heavily on animal and in vitro data, which is worth keeping in mind when evaluating confidence levels.

The compounds in this stack have been studied individually for telomere biology, extracellular matrix remodelling, gene expression regulation, sirtuin pathway activation, and mitochondrial function. The combination has not been directly studied in peer-reviewed literature.

Researchers interested in complementary approaches may find the Hallmarks Stack or the Khavinson Triple relevant for comparison. Full compound catalogue available at our Research Compound Catalogue.

References

1. Khavinson VKh et al. (2004). Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine. PMID: 15455129

2. Khavinson V et al. (2020). AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules (Basel, Switzerland). PMID: 32019204

3. Kozina LS et al. (2007). Antioxidant properties of geroprotective peptides of the pineal gland. Archives of Gerontology and Geriatrics. PMID: 17317455

4. Khavinson VK et al. (2000). Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development. PMID: 11087911

5. Anisimov VN et al. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. PMID: 19830585

6. Maquart FX et al. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. The Journal of Clinical Investigation. PMID: 8227353

7. Pickart L et al. (2017). The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sciences. PMID: 28212278

8. Wang Y et al. (2024). Rigid-flexible nanocarriers loaded with active peptides for antioxidant and anti-inflammatory applications in skin. Colloids and Surfaces B: Biointerfaces. PMID: 38394858

9. Braidy N et al. (2020). NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis. Experimental Gerontology. PMID: 31917996

10. Khaidizar FD et al. (2021). Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process. International Journal of Molecular Sciences. PMID: 33918226

11. Vreones M et al. (2023). Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. Aging Cell. PMID: 36515353

12. Pencina KM et al. (2023). MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. The Journals of Gerontology: Series A. PMID: 35182418

13. Orr ME et al. (2024). A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. PMID: 37994989

14. Song J et al. (2025). NAD+ Enhanced Mesenchymal Stromal Cells Effect on Muscle Atrophy by Improving SIRT1-Mediated Mitochondrial Function via NAMPT. Journal of Cachexia, Sarcopenia and Muscle. PMID: 41383117

15. Maynard S et al. (2022). Lamin A/C impairments cause mitochondrial dysfunction by attenuating PGC1α and the NAMPT-NAD+ pathway. Nucleic Acids Research. PMID: 36099415

Every compound in the biohacker.team catalogue — including Epithalon, GHK-Cu, and NAD+ — is sourced from manufacturers that provide HPLC purity certificates and third-party mass spectrometry verification on every production batch. Certificates of Analysis (COAs) are available on request for all compounds. We do not carry compounds that cannot meet a minimum 98% purity threshold by HPLC analysis. Lot traceability is maintained from synthesis through storage and fulfilment. Our sourcing process is documented at About biohacker.team. This post was researched and written by the biohacker.team research staff — a team with backgrounds in biochemistry, pharmacology, and translational research methodology. We have no financial relationship with the authors of any cited studies.

For research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.